• Sorafenib (BAY-43-9006): Optimizing Cancer Biology Workflows

  2026-05-20

  Sorafenib (BAY-43-9006) is a versatile cancer biology research tool, enabling precise interrogation of angiogenic and proliferative pathways in tumor models. This guide translates bench-proven protocols and troubleshooting wisdom into actionable strategies, empowering researchers to maximize reproducibility and insight with APExBIO’s Sorafenib.

• BFH772 (VEGFR2 Inhibitor): Technical Use and Protocol Parame

  2026-05-20

  BFH772 is a highly selective VEGFR2 inhibitor for researchers needing precise modulation of VEGFR2-mediated angiogenesis, especially in tumor angiogenesis studies. It is not suitable for workflows requiring water-soluble compounds or broad-spectrum kinase inhibition due to its defined selectivity and solubility properties.

• Mubritinib as a Complex I Inhibitor in OXPHOS-Dependent AML

  2026-05-19

  Baccelli et al. (2019) reveal that Mubritinib (TAK 165), previously identified as a HER2 inhibitor, acts as a potent and selective inhibitor of mitochondrial complex I in acute myeloid leukemia (AML). Their work uncovers a metabolic vulnerability in poor outcome AML subtypes reliant on oxidative phosphorylation, providing a mechanistic rationale for targeting OXPHOS in chemotherapy-resistant AML.

• Erastin as a Ferroptosis Inducer: Protocols and Optimization

  2026-05-19

  Erastin enables precise induction of ferroptosis in RAS/BRAF-mutant tumor cells, transforming cancer biology research and immunotherapy studies. This guide details experimental workflows, troubleshooting, and the latest immunological insights, ensuring reproducible results with APExBIO's validated reagent.

• ECL Chemiluminescent Substrate Detection Kit for Low-Abundan

  2026-05-18

  The ECL Chemiluminescent Substrate Detection Kit (Hypersensitive) enables reliable immunoblotting detection of low-abundance proteins, offering picogram-level sensitivity and long-lasting signals. This article unpacks practical workflows, protocol optimizations, and troubleshooting insights, drawing on recent oral cancer research to guide advanced applications.

• Eltanexor Modulates Wnt/β-catenin to Suppress Colorectal Tum

  2026-05-18

  This study demonstrates that Eltanexor (KPT-8602), a second-generation XPO1 inhibitor, reduces colorectal cancer (CRC) tumorigenesis by disrupting Wnt/β-catenin signaling and decreasing COX-2 expression. The research provides mechanistic evidence for targeting nuclear export in CRC chemoprevention, with translational relevance for hereditary and sporadic CRC risk.

• Minocycline HCl: Optimizing EV and Neuroinflammation Workflo

  2026-05-17

  Minocycline HCl empowers scalable, reproducible research in both inflammation and regenerative medicine by combining antimicrobial, anti-inflammatory, and neuroprotective properties. APExBIO’s high-purity formulation enables robust EV workflow integration and improved outcome fidelity across diverse cell models.

• Quizartinib (AC220): Precision FLT3 Autophosphorylation Inhi

  2026-05-16

  Explore the advanced mechanistic precision of Quizartinib (AC220) in acute myeloid leukemia (AML) research. This article provides deep scientific insights into FLT3 autophosphorylation inhibition and guides assay optimization beyond standard protocols.

• ROS-Scavenging Smart Hydrogel for Diabetic Wound Therapy

  2026-05-15

  A novel thermosensitive hydrogel integrates hollow mesoporous MnO2 nanozymes and TGF-β1 to address diabetic wound healing barriers. The material couples controlled ROS scavenging with immune modulation and mechanosensitive release, showing accelerated healing and potential translational impact.

• AT-406 (SM-406) in Apoptosis Pathway Activation: Applied Wor

  2026-05-15

  AT-406 (SM-406) empowers cancer researchers to induce apoptosis with precision by antagonizing key IAPs. This article details step-by-step protocols, optimization strategies, and troubleshooting tips grounded in recent mechanistic breakthroughs—enabling robust data and reproducible results in both in vitro and in vivo models.

• Tetramethylrhodamine Ethyl Ester Perchlorate: Decoding Mitoc

  2026-05-14

  Explore the unique role of Tetramethylrhodamine ethyl ester perchlorate as a rhodamine-like fluorescent dye for advanced live-cell mitochondrial membrane potential studies. This article uncovers mechanistic insights from recent research and bridges them to practical assay optimization.

• Triacetin Catalyzes Aldehyde Generation in E-Cigarette Aeros

  2026-05-14

  This study elucidates how triacetin, a common e-liquid additive, enhances the formation of toxic aldehydes during e-cigarette aerosolization. Using isotope labeling and NMR, the authors reveal a catalytic pathway mediated by acetic acid, informing risk assessment for inhaled flavoring agents.

• Cabozantinib (XL184) in RCC: Protocols, Adaptation, and Trou

  2026-05-13

  Cabozantinib (XL184) offers unmatched flexibility for dissecting timescale-dependent signaling networks and adaptation in renal cell carcinoma models. This guide translates state-of-the-art phosphoproteomic insights into actionable workflows, troubleshooting strategies, and protocol enhancements for robust antiangiogenic and kinase inhibition research.

• Mubritinib (TAK 165): Selective Mitochondrial Inhibitor in C

  2026-05-13

  Mubritinib (TAK 165) is a highly selective mitochondrial complex I inhibitor with primary activity in chemotherapy-resistant AML and PEL models. Contrary to early assumptions, its HER2 inhibition lacks clinical relevance, with major effects observed through suppression of oxidative phosphorylation. Selectivity and tolerability make Mubritinib a key tool in cancer biology and apoptosis assays.

• 7ACC2: Redefining Tumor Metabolism and Immunometabolic Strat

  2026-05-12

  Explore how 7ACC2, a dual-action monocarboxylate transporter 1 inhibitor, is catalyzing a paradigm shift in cancer metabolism research. This article synthesizes recent immunometabolic breakthroughs, such as the 25-hydroxycholesterol–AMPK–STAT6 axis in tumor-associated macrophages, with actionable experimental guidance for translational researchers. By bridging mechanistic insight and strategic application, it positions 7ACC2 as a cornerstone tool in dissecting and targeting metabolic vulnerabilities for next-generation oncology therapies.

15669 records 1/1045 page Next 12345 下5页 Last page